Salivary gland carcinoma
MONDO:0000521A carcinoma that arises from the major or minor salivary glands. Representative examples include carcinoma ex pleomorphic adenoma, adenocarcinoma, adenoid cystic carcinoma, and mucoepidermoid carcinoma.
Also known as: salivary gland cancer, carcinoma of saliva-secreting gland, carcinoma of salivary gland, carcinoma of the salivary gland, saliva-secreting gland carcinoma, salivary gland carcinoma, salivary carcinoma
2990 clinical trials for this condition and its sub-types, 26 tagged with Salivary gland carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Salivary gland carcinoma
-
Major salivary gland carcinoma 6 trials
6 sub-types
- Carcinoma of parotid gland 0 trials Sub-types →
- Major salivary gland adenoid cystic carcinoma 0 trials Sub-types →
- Major salivary gland carcinoma ex pleomorphic adenoma 0 trials Sub-types →
- Major salivary gland mucoepidermoid carcinoma 0 trials Sub-types →
- Sublingual gland carcinoma 0 trials Sub-types →
- Submandibular gland cancer 0 trials Sub-types →
-
2 sub-types
- Parotid gland squamous cell carcinoma 0 trials
- Salivary gland adenosquamous carcinoma 0 trials
-
Salivary duct carcinoma 3 trials
-
2 sub-types
-
Mammary analog secretory carcinoma 0 trials
-
Minor salivary gland carcinoma 0 trials
1 sub-type
-
1 sub-type
-
Salivary gland large cell carcinoma 0 trials
-
1 sub-type
-
Salivary gland small cell carcinoma 0 trials
Most studied deeper sub-types
-
Two-Drug combo targets Hard-to-Treat salivary gland tumors
Disease control Recruiting nowResearchers are testing whether combining abiraterone and dalpiciclib can shrink recurrent or metastatic salivary gland cancer that is AR-positive and HER-2-negative. The trial enrolls up to 36 adults who have no curative surgery or radiation options. Participants take both drugs…
Phase 2 • Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Smart drugs take on rare salivary gland cancer in new trial
Disease control Recruiting nowThis phase II trial is testing whether newer targeted drugs (trastuzumab emtansine and trastuzumab deruxtecan) work better than standard chemotherapy plus trastuzumab for people with HER2-positive or HER2-low salivary gland cancer that has come back, spread, or cannot be removed.…
Phase 2 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Drug duo takes on rare head and neck tumors
Disease control Recruiting nowThis trial investigates whether combining two drugs, camrelizumab and famitinib, can help people with rare head and neck cancers that have spread or cannot be removed by surgery. The study includes four types of these cancers and aims to see how safe and effective the treatment i…
Phase 1/2 • Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New targeted chemo aims to hit tumors harder, spare healthy tissue
Disease control Recruiting nowThis early-phase trial tests AVA6000, a chemotherapy drug that is designed to activate only in tumors, potentially reducing side effects. About 158 adults with advanced solid tumors (like breast, ovarian, or salivary gland cancer) will receive the drug intravenously. The main goa…
Phase 1 • Sponsor: Avacta Life Sciences Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New precision therapy trial aims to match salivary gland cancer patients with the right drug
Disease control Recruiting nowThis study tests whether giving targeted therapy or chemotherapy based on specific markers (HER2, NTRK, AR, TROP-2) found in a patient's tumor can shrink or control salivary gland cancer. About 39 adults with advanced or recurrent cancer will receive a treatment matched to their …
Phase 2 • Sponsor: Peking Union Medical College • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug combo shows promise for rare salivary gland cancer
Disease control Recruiting nowThis study tests a new drug (MRG003) alone or with another drug (putrelimab) in people with salivary gland cancer that has come back or spread. The goal is to see if these treatments can shrink tumors or stop them from growing. About 90 adults will take part, and the study is not…
Phase 2 • Sponsor: Ji Dongmei • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New pill shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called VMD-928, taken as a pill, either alone or with another cancer drug (pembrolizumab). It is for adults with advanced solid tumors or lymphoma that have not responded to or are no longer controlled by available treatments. The goal is to …
Phase 1/2 • Sponsor: VM Oncology, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Common pain gel could shield cancer patients from radiation burns
Prevention Recruiting nowThis study tests whether a gel containing diclofenac, a common anti-inflammatory drug, can prevent severe skin irritation caused by radiation therapy. About 156 adults with head/neck or breast cancer will apply the gel or a placebo to the treated skin three times daily during the…
Sponsor: The Second Affiliated Hospital of Hainan Medical University • Aim: Prevention
Last updated Jun 27, 2026 12:03 UTC
-
Scientists hunt for immune clues in rare salivary gland cancers
Knowledge-focused Recruiting nowThis study is for 300 people with salivary gland tumors (both cancerous and non-cancerous) to learn how the immune system reacts to these rare cancers. Researchers will collect tumor tissue and blood samples before and after treatment to find immune markers that might predict how…
Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
New registry tracks Post-Surgery combo therapy for rare head and neck cancer
Knowledge-focused Recruiting nowThis study is a registry that collects information from 100 people with advanced salivary gland cancer who receive radiation and chemotherapy together after surgery. The goal is to create a database to track how well the treatment works and its side effects. It is not testing a n…
Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC